Finance

Beta
Lists
KYKOF:OTCMKTS
Kyowa Kirin Co Ltd
$14.42
0.00%
(0.00) 1D
May 12, 3:52:47 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KYKOF...
Mkt. cap
1.21T
Avg. vol.
1.18K
Volume
0.00
52-wk high
$18.00
52-wk low
$12.42
Beta
0.46
Shares outstanding
525.64M
No. of employees
5K
Mkt. cap
1.21T
Avg. vol.
1.18K
Volume
0.00
52-wk high
$18.00
52-wk low
$12.42
Beta
0.46
Shares outstanding
525.64M
No. of employees
5K
News stories
From sources across the web
Profile
Kyowa Kirin Co., Ltd. is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and was among the 40 largest in the world by revenue in 2012. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. Wikipedia
About Kyowa Kirin Co Ltd
CEOMasashi Miyamoto
Employees5.16K
FoundedJul 1, 1949
Headquarters-
SectorPharmaceutical industry
Websitekyowakirin.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
125.93B
118.80B
147.38B
118.47B
Cost of goods sold
37.27B
28.20B
37.87B
30.22B
Cost of revenue
37.27B
28.20B
37.87B
30.22B
Research and development expenses
23.94B
24.33B
24.35B
27.16B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
40.78B
38.72B
31.35B
41.07B
Operating expense
77.03B
63.05B
72.15B
71.01B
Total operating expenses
114.30B
91.25B
110.02B
101.23B
Operating income
11.63B
27.55B
37.35B
17.23B
Other non operating income
1.19B
-1.69B
13.50B
-7.71B
EBT including unusual items
14.12B
25.95B
39.30B
13.93B
EBT excluding unusual items
14.12B
25.95B
51.23B
13.93B
Income tax expense
3.96B
9.67B
4.86B
1.89B
Effective tax rate
28.08%
37.26%
12.36%
13.59%
Other operating expenses
12.30B
-
3.92B
-
Net income
10.15B
16.28B
34.44B
12.03B
Net profit margin
8.06%
13.70%
23.37%
10.16%
Earnings per share
-
-
-
-
Interest and investment income
1.38B
1.18B
2.71B
5.68B
Interest expense
-2.54B
-529.00M
-28.00M
-2.27B
Net interest expenses
-1.16B
653.00M
2.68B
3.41B
Depreciation and amortization charges
-
-
12.54B
-
EBITDA
17.85B
33.97B
44.74B
24.88B
Gain or loss from assets sale
506.00M
-
2.77B
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer